(Albany, US) September 11, 2026- DelveInsight’s “Epilepsy Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Epilepsy Treatment Landscape @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
Key Takeaways from the Epilepsy Pipeline Report
DelveInsight’s Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
The leading Epilepsy Companies include Harmony Biosciences, Bright Minds Biosciences, Stoke Therapeutics, Neurona Therapeutics, IAMA Therapeutics, and others.
Promising Epilepsy Pipeline Therapies such as EPX-100, BMB-101, STK-001, NRTX-1001, IAMA-6, and others.
The companies which have their Epilepsy drug candidates in the most advanced stage, i.e. Phase III, include Harmony Biosciences.
Gain in-depth knowledge of key Epilepsy clinical trials, emerging drugs, and market opportunities @ Epilepsy Clinical Trials Assessment
Epilepsy Overview
Epilepsy is one of the most common serious brain conditions, affecting over 50 million people worldwide. It is a neurological disorder characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological, and social consequences, with a bimodal incidence distribution carrying the highest risk in infants and older age groups. An epileptic seizure is a transient behavioral change — objective signs or subjective symptoms such as loss of awareness, stiffening, jerking, a sensation rising from the abdomen to the chest, a smell of burnt rubber, or déjà vu — caused by abnormal excessive or synchronous neuronal activity in the brain.
Epilepsy is a chronic, non-communicable disease of the brain marked by recurrent seizures unpredictable in frequency. A seizure is generally defined as a sudden alteration of behavior due to a temporary change in the brain’s electrical functioning; normally, the brain continuously generates tiny electrical impulses in an orderly pattern that travel along neurons and throughout the body via neurotransmitters, and seizure episodes result from excessive electrical discharges in a group of brain cells. The pathophysiology of epilepsy involves the conversion of a normal network into a hyperexcitable one, associated with processes that disturb extracellular ion homeostasis, alter energy metabolism, change receptor function, and alter transmitter uptake. Within the central nervous system, excessive release of excitatory glutamate overactivates NMDA receptors, causing an excessive influx of Ca2+ ions; the resulting overflow activates cytoplasmic proteases such as calpain I, which break down cytoskeletal and other proteins, and neuronal nitric oxide synthase (nNOS), which raises nitric oxide production and generates the free radical peroxynitrite, damaging DNA and ultimately leading to neuronal cell death.
Accurate diagnosis of the type of epilepsy a person has is crucial for finding an effective treatment, and there are many different ways to successfully control seizures. Drugs used to treat epilepsy work by decreasing the brain’s electrical activity — by preventing neuronal depolarization through blocking sodium or calcium channels, enhancing potassium channel function, inhibiting glutamate-mediated excitation, or promoting GABA-mediated inhibition. A neurologist’s choice of seizure medication is based on seizure type, age, other medical conditions, and potential side-effect profile, generally starting at a low dose with increases at regular intervals as needed to control seizures with the lowest effective dose; when a first drug fails, clinicians often add a second drug before deciding whether to withdraw the initial medication, and because of their mechanism of action, virtually all seizure medications carry CNS side effects such as sleepiness.
Epilepsy Emerging Drugs Profile
EPX-100: Harmony Biosciences EPX-100 is a potential new treatment for people with Dravet syndrome and Lennox-Gastaut Syndrome. It is a repurposed antihistamine, used in the 1950s and 1960s to treat itchiness, thought to suppress seizures through action on serotonin signaling pathways — a mechanism distinct from its antihistaminic properties. Scientists believe people with Dravet syndrome and Lennox-Gastaut Syndrome may have alterations in serotonin signaling, though the exact mechanism by which EPX-100 affects brain serotonin systems to reduce seizures remains unclear. According to the company’s pipeline, the drug is in the Phase III stage of development for Dravet syndrome and the Phase II stage for Lennox-Gastaut Syndrome.
BMB-101: Bright Minds Biosciences BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity across a host of in-vitro and in-vivo non-clinical tests, exhibiting strong Gq signaling coupled with minimal beta-arrestin recruitment compared to lorcaserin. Serotonin (5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol, and nicotine; clinical trial and animal study results suggest 5-HT2C receptor agonists may hold therapeutic potential in addiction by decreasing opioid intake and impulsive behavior. Currently, the drug is in the Phase II stage of clinical trial evaluation for the treatment of Epilepsy.
STK-001: Stoke Therapeutics STK-001 is an investigational medicine for the treatment of Dravet syndrome, currently being evaluated in ongoing clinical trials. It is a proprietary antisense oligonucleotide (ASO) that Stoke believes has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels and thereby reduce both seizure occurrence and significant non-seizure comorbidities. Currently, the drug is in the Phase III stage of clinical trial evaluation for the treatment of Dravet Syndrome.
NRTX-1001: Neurona Therapeutics NRTX-1001 consists of inhibitory neurons targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. Delivered as a single, one-time dose, it is intended to persist and provide long-term seizure suppression; in preclinical studies, it provided seizure-freedom to the majority of the cell treatment group without signs of dose-limiting toxicity. These preclinical safety and efficacy data have led to an FDA-cleared Phase I/II clinical trial of NRTX-1001 for drug-resistant temporal lobe epilepsy.
IAMA-6: IAMA Therapeutics IAMA-6 is an orally administered small molecule designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. Elevated NKCC1 activity is implicated in various pathological conditions, underscoring the potential of NKCC1 inhibition in treating both idiopathic and secondary forms of autism spectrum disorder (ASD), refractory epilepsy, Dravet Syndrome, and other neurological disorders. Applicable across multiple CNS indications, IAMA-6 has demonstrated safety and favorable tolerability in pre-clinical studies. Currently, the drug is in the Phase I stage of clinical trial evaluation for the treatment of Epilepsy.
The Epilepsy Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy, with aggregate therapies developed by each company.
It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Epilepsy treatment.
Epilepsy Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
Epilepsy drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the Epilepsy market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Epilepsy Unmet Needs
Epilepsy Companies
Harmony Biosciences, Bright Minds Biosciences, Stoke Therapeutics, Neurona Therapeutics, IAMA Therapeutics, and others.
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Epilepsy Products have been categorized under various Molecule types such as:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Epilepsy Pipeline! @ Epilepsy Market Drivers and Barriers, and Future Perspectives
Scope of the Epilepsy Pipeline Report
Coverage- Global
Epilepsy Companies- Harmony Biosciences, Bright Minds Biosciences, Stoke Therapeutics, Neurona Therapeutics, IAMA Therapeutics and others.
Epilepsy Pipeline Therapies- EPX-100, BMB-101, STK-001, NRTX-1001, IAMA-6 and others.
Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Epilepsy Pipeline Analysis Today! @ Epilepsy Drugs and Companies
Table of Contents
Introduction
Executive Summary
Epilepsy: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Epilepsy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Epilepsy Key Companies
Epilepsy Key Products
Epilepsy – Unmet Needs
Epilepsy – Market Drivers and Barriers
Epilepsy – Future Perspectives and Conclusion
Epilepsy Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: KanishkEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
